Welcome to RLS Global Newsletter No. 9, 2020

Three Regions in Sweden have awarded ChloraSolv on tenders, Kalmar, Stockholm and Skåne. And not to forget and to add on, about 10 different municipalities. From a population perspective, this represent a significant part of the Swedish market potential. More Regions are testing and evaluating the technology and RLS is expecting more positive awards going forward.

The last six months have been a challenging time for many different industries, as well as the healthcare sector. It is pending almost day by day how the industry can interact with the caregivers. However, there is a light in the tunnel and it is getting easier to reach out and “meet” with the different stakeholders.

RLS works in close collaboration with the wound nurses whom are responsible for these patients. Launching a new technology and product on the market demands a lot of insights and know-how from the users as well as from the patients. Recurring customer revenue is a comprehensive indicator that shows the extent to which we are retaining, expanding and growing our customer relationship value. It shows that the introduction of the technology is successful and ChloraSolv starts to become a standard treatment.

Shortly RLS will launch an updated website. The aim is to increase the communication with the care givers with more hands on experiences. Below is one patient case from Stockholm. It really shows the impact of ChloraSolv and the importance to establish a “clean wound” with the aim to support an efficient  wound healing process.   

New exciting pre-clinical data for ChloraSolv
RLS has also communicated about new, exciting data for Biofilm. Staphylococcus aureus and Pseudomonas aeruginosa are two common bacteria that form biofilms in chronic wounds. A biofilm is formed by a high number of bacteria that protect themselves through a secretion of a viscous barrier. A consequence is that the bacteria is protected from antibiotics and several antiseptics.

The purpose of the study was to investigate the effect of ChloraSolv on these two bacteria. The results show that ChloraSolv has a rapid effect on both bacteria. In Staphylococcus aureus biofilm, 33% of the bacteria were killed in 30 seconds and more than 81% in five minutes. The effect on Pseudomonas aeruginosa is more immediate and kills more than 95% after 30 seconds. After five minutes, 97% of the bacteria are gone from the wound model.

The Biofilm data is really encouraging for ChloraSolv. All new data, customers feedback, new tenders as well as stronger footprint on the market provides the confidence in ChloraSolv drive our market penetration.

Not to forget…  ChloraSolv 01. RLS has submitted an Abstract to EWMA (European Wound Management Meeting) and the plan is to share data already at the annual meeting in November. It is the first time a few data points will be communicated to the wound care community.

Below, one patient treated with ChloraSolv the last months:

As mentioned before, an efficient debridement method is key to stimulate an efficient healing process. The combination with antimicrobial effect as well as softens of devitalized tissue are unique with ChloraSolv.

It is a very exciting moment for us at RLS Global despite a very challenging time on the market. Stay tune… more to come!

Karin Fischer
CEO RLS Global